The evidence for omega-3s is genuinely solid in some areas and genuinely overhyped in others. EPA and DHA the two marine fatty acids that do the actual clinical work have consistent data behind cardiovascular benefits, but only at therapeutic doses: 1–4 g/day of combined EPA+DHA. The general wellness market routinely sells products at a fraction of that and then doesn’t understand why the outcomes don’t match the research. Dose matters. Source matters. Concentration matters.
Strava Healthcare manufactures omega-3 softgel capsules in India using fish oil concentrated to pharmaceutical-grade EPA+DHA levels, in standard and high-concentration formats, for nutraceutical brands, pharmaceutical companies, and private label buyers.
Omega-3 Soft gels are growing in demand in the countries like United Kingdom, Myanmar, Thailand, Philippines, Ghana, Laos, Malaysia, Nigeria, Algeria, Morocco, Oman, Guatemala, Panama, Ecuador, Honduras, Bolivia, Peru and Paraguay.
EPA and DHA what they actually do
EPA (eicosapentaenoic acid) is the primary anti-inflammatory fatty acid in the omega-3 family. It competes with arachidonic acid in eicosanoid synthesis, shifting the balance toward less inflammatory mediators. If you’re formulating for triglyceride reduction or cardiovascular risk, EPA is the one doing most of that work.
DHA (docosahexaenoic acid) is structural — a major component of neuronal membranes, the retina, and sperm. It accounts for a large fraction of polyunsaturated fat in brain grey matter. Prenatal and infant cognitive development, visual development, and neuroprotective applications are all DHA territory. Most clinical situations benefit from both together, though inflammatory and cardiovascular applications tend to respond better to EPA-dominant ratios.
Where it's used
Hypertriglyceridaemia is the best-documented clinical application at therapeutic doses. Secondary cardiovascular prevention has solid evidence behind it. Prenatal supplementation for foetal brain and retinal development is standard of care in many markets. Cognitive support in older adults, rheumatoid arthritis adjunct therapy, dry eye management, and sports recovery round out the common formulation targets.
A note on manufacturing
Fish oil is one of the harder raw materials to work with in softgel production. Peroxidation is a real problem — poorly stored or processed fish oil goes rancid in ways that aren’t always obvious to the end consumer but show up clearly in peroxide and anisidine values. We use nitrogen-flushed encapsulation to cut down oxidation during manufacturing.
Every batch is tested for EPA and DHA potency (measured against actual content, not estimated from label), peroxide value, anisidine value, mercury, lead, arsenic, cadmium, and microbiological purity. PCBs and dioxins tested on request. Third-party COAs for all batches.
For B2B and pharma buyers
Contract manufacturing with custom EPA: DHA ratios, gelatin type, and enteric coating on request. Private label products ready to market. Bulk supply for pharma distributors and export.
Product Specifications
| Parameter | Details |
|---|---|
| Active ingredients | Fish oil concentrate (EPA + DHA as triglycerides or ethyl esters) |
| Standard strength | 1000 mg fish oil — 180 mg EPA / 120 mg DHA per softgel |
| High concentration | 500 mg EPA + 250 mg DHA per softgel (or custom ratio) |
| Dosage form | Softgel capsule |
| Shell | Gelatin-based — bovine or fish gelatin, specify at enquiry |
| Pack sizes | 30s, 60s, 90s bottle; bulk drums |
| Shelf life | 24 months |
| Storage | Below 25°C, away from light |
Frequently Asked Questions
A standard 1,000 mg fish oil softgel delivers around 300 mg of combined EPA+DHA — roughly 30% concentration. Concentrated fish oil gets that to 60–90% in the same capsule size. For anyone trying to hit therapeutic doses for triglyceride lowering or cardiovascular protection, the concentrated form means fewer capsules per day. For general wellness where the dose threshold is less critical, standard concentration is fine.
Yes, somewhat. Triglyceride (TG) form is how omega-3s naturally occur in fish. Re-esterified triglycerides (rTG) are processed but return to TG form. Ethyl esters (EE) are cheaper and dominate the pharmaceutical market — absorbed a bit less efficiently, but with real clinical data behind them at therapeutic doses. For premium product positioning and better bioavailability, rTG is worth the extra cost. For a mainstream product, EE is perfectly serviceable.
Yes. Enteric coating delays release until the small intestine and eliminates the fishy aftertaste that drives non-compliance. It adds cost, but for a daily-use product it often pays for itself in retention.